Skip to main content
CJC-1295 No DAC
Pulsatile Growth Hormone Research
Recovery Systems1 / 3
Recovery Systems
New

CJC-1295 No DAC

CJC-1295 (no DAC) is a synthetic modified GHRH analogue of 29 amino acids synthesised as a tetrasubstituted GRF 1-29 variant, studied in GH-axis research for its role in driving short, pulsatile GH release.

No DAC ≠ DAC. CJC-1295 with DAC: The Research, History and Status

Quality information

A short-acting GHRH analogue studied for pulsatile growth hormone release — investigated in sleep quality, overnight recovery, and steady daily vitality.

For Research Use Only — Not for Human Consumption.

Sold strictly for in vitro laboratory research purposes.

Listed under the WADA 2026 Prohibited List.

Not for use by competitive athletes in sanctioned sports.

€40€5010 mg · Incl. VAT · €4.00 / mg
1
Storage
Store 2–8 °C. Use reconstituted vial within 14 days.

Up closeMuscle & Sleep

CJC-1295 No DAC

Recovery Systems

€4010 mgIn stock
What this peptide is for

Pulsatile Growth Hormone Research.

CJC-1295 without DAC (modified GRF 1-29, CAS 863288-34-0) is a tetrasubstituted GHRH analogue with a short plasma half-life. Research has examined its role in supporting natural GH pulsatility, IGF-1 signalling, and sleep architecture. Formula C152H252N44O42, MW 3367.9 g/mol.

Linked research
  • — Teichman et al. — CJC-1295 pharmacokinetics and GH/IGF-1 response
  • — Ionescu & Frohman — GHRH analogue effects on endogenous GH pulsatility

Research context only. Not medical advice. Not for human or veterinary use.

Specification
  • 10 mg lyophilised powder per vial
  • Reconstitute with bacteriostatic water before use
  • Store lyophilised at 2–8 °C, keep from light
  • Once reconstituted, refrigerate and use within 14 days
What arrives in the box
  • One 10 mg lyophilised CJC-1295 (No DAC) vial
  • Tamper-evident cap with batch-coded label
  • Storage card with reconstitution guidance
Pharmacology

What the research reports about this molecule.

Classic parameters from peer-reviewed literature. Not human dosing guidance — read alongside the PubMed references on /learn.

Sequence
Modified GHRH 1-29 (29 amino acids)
Molecular weight
3367 Da
Half-life
Not established in published human studies
Mechanism
Pulsatile GH release via GHRH-R
Research domain
GH-axis research
Reconstitution
Bacteriostatic water, USP
Storage
Sealed: 2–8 °C, away from light; reconstituted: 2–8 °C, use within 14 days
Handling & storage

From arrival to storage.

Laboratory handling notes for this compound. Peptyds products are supplied for research use only, not for human or veterinary use, so we give no dosing or administration guidance.

  1. 1

    Store the sealed vial at 2–8 °C, away from light

  2. 2

    Reconstitute with 2 mL bacteriostatic water — swirl gently

  3. 3

    Label the vial with its batch number and reconstitution date

  4. 4

    Refrigerate reconstituted vial; use within 14 days

Handling guide

Read the reconstitution guide

Reconstitution and storage for laboratory handling, step by step.

Reconstitution calculator

Research use only

Syringe

Peptide in vial

Bacteriostatic water

Concentration5 mg/mL

Target dose

Pull syringe to

5

units · 0.05 mL

01020304050607080901005

Concentration

5

mg/mL

Doses per vial

40

doses

U-50 2.5 · U-40 2 units

For laboratory research calculation only. Not medical or dosing advice, and not for human or veterinary use.

Others researching Muscle & Sleep also compare

Questions, answered plainly

Everything worth asking before you order.

Shipping, storage, quality, and when to speak to a clinician — without the runaround.

Where can I find product information?

Product pages contain product details and research information. Contact us if you have a question about an item.

Should I speak to a clinician before using a peptide?

We recommend it — especially if you are pregnant, nursing, managing a medical condition, or combining peptides with prescribed medication. Our product pages are educational. They are not medical advice and they do not replace a conversation with a qualified practitioner.

How should I store my order when it arrives?

Follow the storage and handling guidance on the specific product page.

Are research peptides banned by WADA?

Several research peptides we list — including BPC-157, TB-500, GHRPs, and IGF-1 LR3 — are listed on the WADA Prohibited List under classes S0 (unapproved substances) and S2 (peptide hormones and growth factors). They are prohibited at all times, in and out of competition.

How do I reconstitute a lyophilised peptide vial?

Bring both the lyophilised vial and the bacteriostatic water to room temperature, equalise pressure with a sterile vented needle, then inject the solvent slowly down the side of the vial. Swirl gently — never shake — until clear, and refrigerate at 2–8 °C.

How much bacteriostatic water should I add to my peptide vial?

The calculation is peptide mass (mg) ÷ desired concentration (mg/mL) = volume of bacteriostatic water in mL. For example, a 5 mg vial at 1 mg/mL needs 5 mL; at 2 mg/mL, 2.5 mL. Every Peptyds product page carries a suggested reconstitution volume tuned to the vial size.

How long does a reconstituted peptide stay stable in the fridge?

Most lyophilised peptides reconstituted with bacteriostatic water remain stable for 28–30 days at 2–8 °C, protected from light. A handful of short, fragile sequences — Epithalon among them — drop to roughly 14 days. Never freeze a reconstituted vial.

What side effects are most commonly reported across peptide research?

Across published trials and case series, the most frequent reported events are injection-site reactions (redness, induration, transient discomfort), headache, mild nausea, and temporary fatigue. GLP-1 and dual-agonist class peptides add dose-dependent gastrointestinal effects.

Who should not use peptides?

Peptides are not appropriate for anyone who is pregnant, nursing, planning conception, under 18, managing active cancer, or on immunosuppressants — and competitive athletes governed by WADA must avoid every peptide on the prohibited list. Anyone with a personal or family history of melanoma should specifically avoid melanocortin-receptor agonists.